Additional Metadata
Keywords advanced cancer, cancer combination chemotherapy, cancer palliative therapy, cancer patient, cetuximab, cisplatin, clinical trial, docetaxel, drug safety, editorial, febrile neutropenia, fluorouracil, gastrointestinal toxicity, head and neck carcinoma, human, incidence, local therapy, maximum tolerated dose, phase 1 clinical trial, priority journal, squamous cell carcinoma, treatment outcome
Persistent URL dx.doi.org/10.1200/JCO.2009.23.6703, hdl.handle.net/1765/19623
Citation
Hamberg, A.P., & Verweij, J.. (2009). Phase I drug combination trial design: Walking the tightrope. Journal of Clinical Oncology, 27(27), 4441–4443. doi:10.1200/JCO.2009.23.6703